biotech
biotech Articles
Over the past week, Alere and a few biotech other companies made absolutely massive runs, either up and down.
Published:
Last Updated:
TherapeuticsMD shares were active on Thursday after an analyst report suggested that the stock could have up to almost 200% upside.
Published:
Last Updated:
Therapure Biopharma has announced that, due to current conditions in capital markets, it would postpone its initial public offering.
Published:
Last Updated:
Sinovac Biotech Ltd. (NASDAQ: SVA) was riding high early Thursday morning, following the offer for a potential buyout, but it looks like this company doesn’t want to take the bait. It announced...
Published:
Last Updated:
Gilead Sciences reported better-than-expected fourth-quarter financial results after the markets closed on Tuesday.
Published:
Last Updated:
Gilead Sciences is set to release its fourth-quarter earnings report after the markets close on Tuesday.
Published:
Last Updated:
In its IPO, Beigene plans to offering more than 5 million American depositary shares in an expected price range of $22 to $24 apiece.
Published:
Last Updated:
Proteostasis Therapeutics expects to price more than 3 million shares in the range of $12 to $14 per share in an initial public offering is valued up to $62 million.
Published:
Last Updated:
Alere absolutely skyrocketed in Monday’s regular session following the announcement that it will be acquired by Abbott Laboratories.
Published:
Last Updated:
A recent Jefferies research note indicates that the multiples for the four largest biotechs have dipped below that of the S&P for the first time since early in 2011, despite displaying higher...
Published:
Last Updated:
Exelixis shares were rising early Monday following the release of positive results from its late-stage trial of cabozantinib.
Published:
Last Updated:
24/7 Wall St. has collected three big FDA decisions coming up in February and added some color, along with the trading range and price target.
Published:
Last Updated:
After the announcement that its Phase 2 trial of Ruxolitinib would be stopped a few analysts took a deeper look at Incyte and realized that it might not be as bad as initially thought.
Published:
Last Updated:
Amgen reported better-than-expected fourth-quarter financial results after the markets closed Thursday.
Published:
Last Updated:
Celgene reported mixed fourth-quarter financial results before the markets opened on Thursday.
Published:
Last Updated: